BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte (MXCT)MaxCyteCompany update

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation

Open original release

Related news

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MXCTMaxCyte2026-03-23 12:05 EST

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-07-01 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPTSarepta Therapeutics2026-03-31 20:05 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-06-05 12:01 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

MaxCyte

MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.

Recent company news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MXCTMaxCyte2026-03-31 20:05 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-03-24 20:05 EST

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MXCTMaxCyte2026-03-23 12:05 EST

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Stock data

Close
1.02 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States